FI90777B - Method for preparing cytostatically active rhodomycinone derivatives - Google Patents

Abstract

Novel cytostatically active anthracyclines of the formula I, which are optionally present as a salt of an inorganic or organic acid <IMAGE> in which the radical R<1> is hydrogen or hydroxyl, R<2> is hydrogen, a structure of the formula II or IV or together with R<3> is a structure of the formula III, R<3> is hydrogen, a structure of the formula II or IV or together with R<2> is a structure of the formula III, R<4> is hydrogen, an acyl group, trimethylsilyl, a structure of the formula II or a structure of the formula IV <IMAGE> R<5> in this case is hydrogen, methyl, hydroxymethylene, acyloxymethylene or alkyloxymethylene, R<6> is hydrogen, hydroxyl, acyloxy, alkyloxy, allyloxy, benzyloxy or halogen, R<7> has the same meaning as R<6> and can additionally be NH2, NHacyl, N(alkyl)3, N(CH2CN)2, NH(CH2CN) or azido, and R<8> has the same meaning as R<6>, where the following compounds of the formula I are excepted: 1. R<1>=R<3>=R<4>=H, R<2>= alpha -L-daunosaminyl 2. R<1>=R<3>=R<4>=H, R<2>= alpha -L-rhodosaminyl or its 4'-acyl derivatives 3. R<1>=R<3>=H, R<2>=R<4>= alpha -L-rhodosaminyl or its 4'-acyl derivatives 4. R<1>=OH, R<3>=H, R<2>=R<4>= alpha -L-rhodosaminyl or its 4'-acyl derivatives 5. R<1>=R<2>=R<3>=H, R<4>= alpha -L-rhodosaminyl or its 4'-acyl derivatives.

Description

90777

Method for preparing cytostatically active β-rhodomycinone derivatives

The invention relates to a process for the preparation of new cytostatically active compounds of formula (I) H 0 HO OR4 10 OH 0 HO OR2 and their salts with inorganic and organic acids, wherein R 2 is hydrogen or a radical of formula (I). II) ch3 20 .. <f> r7 ^ S8 4

and R is hydrogen or a radical of formula II, and formula II

R 1 is hydrogen, hydroxy or benzyloxy, R 7 is NH 2, NH-acyl (C 1 -C 8), N (alkyl) 2 (C 1 -C 8), NH (CH 2 CN) or hydroxy and R 2 is hydrogen or iodine, 30 and the radical of formula II belongs to the L-2 4 series of carbohydrates, with the exception of the compounds in which R = R = H, 4 2 R = H and R = αL-danosaminyl or αL-rhodosaminyl 2 4 or 4'-acyl-αL-rhodosaminyl , R = R = αL-rhodosaminyl or 4'-acyl-α-L-rhodosaminyl or R * H and R 35 α-L-rhodosaminyl or αL-daunosaminyl.

2

Many anthracyclines have a cytostatic effect and some of them are used to treat tumors.

β-rhodomycin derivatives are known from Naturwissenschaft 37 (1950) p. 492 and 42 (1955) p. 154, 5 from U.S. Patent 4,612,371 and from Finnish patent application 875353. Such known compounds are β-rhodomycins (structures of formula I) in which the position 7 and position 10 are attached to L-rhodosamine α-Glycosidically or in which only position 7 is α-glyco-10-linked to L-rhodosamine or L-daunosamine, as are B-iso-rhodomycins (otherwise structures of formula I, but at position 1 of the tetracyclic backbone is OH instead of H), where position 7 and position 10 are each attached to α-L-rhodosamine, as well as photolytic mono-demethylation products of these L-rhodosamine glyco-15 bonds and B-ro-domycinone with oligosaccharide side chains at position 7 or 10 or at positions 7 and 10 and termed cytorodines. Microbial glycosidation of a trisaccharide consisting of L-rhodosamine, L-deoxyfucose and synerulose A at the 7-position of B-rhodomycinone is known from Journal of Antibiotics 33 (1980) p. 1331.

To date, no chemical glycosylation method for β-rhodomycinone has been described. Due to the multiple glycosidation possibilities of the three hydroxyl groups on the A ring of β-rhodomycinone 25 (formula R where R 3 = H), selective glycosidations are much more difficult.

It was found that β-rhodomycinone can be selectively glycosidated using certain protecting groups at positions 7, 9 and 10 and the glycosides thus obtained, in particular 7-O-αL-acosaminyl-β-rhodomycinone and 7-O- (3'-N, N-dimethyl-αL-acosaminyl) -β-rhodomycinone has a cytostatic potency comparable to that of adriamycin.

90777 3

It was therefore an object of the present invention to provide novel mono- and bis-glycosyl-β-rhodomycinones which are characterized by a good cytostatic effect and which are therefore suitable for the treatment of tumors.

This object is achieved according to the invention by preparing the compounds of the formula I as defined above by the process described below, which is the subject of the present invention and is characterized in that 10 a) a compound of the formula

O HO OH

15 ° H

OH 0 HO OH

selectively protected at positions 7 and 9 by structure 20 (III) \

X III

wherein X is a common bidentate protecting group in carbohydrate chemistry, preferably alkylboronyl, phenylboronyl, alkyl ester of orthoalkyl carboxylic acid, preferably methyl ester of orthomoformic acid or ortho-acetic acid ethyl ester, ketal or acetal), preferably isopropylidene, or isopropylidene, preferably isopropylidene position by reaction

with an added carbohydrate of general formula V or VI

CH3 CH3. * 0

·? Ή · v ^ VI

4 where

O

R is as defined above, R 1 is hydrogen, protected hydroxy or benzyloxy, R 1 is NH-acyl (C 1 -C 8), N-alkyl (C 1 -C 8) or protected hydroxy, and g R is oxygen-bonded acyl, such as aliphatic acyloxy (C1-C8), benzoyloxy or substituted benzoyloxy, or b2) protecting the 10-hydroxy group with an acyl, trimethylsilyl or tetrahydropyranyl group, c) removing the protecting group at the 7- and 9-positions, d ) glycosidating the 7-position by reaction with a functionalized carbohydrate of formula V or VI as defined above, e) removing the acyl, trimethylsilyl or tetrahydropyranyl group at the 10-position, f) glycosidating the 10-position of the compound obtained in step e by reaction with a functionalized carbohydrate of formula V or VI or VI with a functionalized carbohydrate, and 6 to 71 g) if R and / or R 'is protected hydroxy, deprotect this group, optionally with a compound of formula I having a compound of formula II radical only at the 7-position, the above-mentioned process steps a, b2, c, d, e and g are carried out; if desired, a compound of formula I having a radical of formula II only in the 10-position is subjected to the above-mentioned process steps a, b2, cjag; and, if desired, a compound of formula I having a radical of formula II in both the 7- and 10-positions, the above-mentioned process steps a, bx, c, d and g or process process steps a, b2, c, d, e , f and g; and, if desired, hydrolyzing the NH acyl group R to give a compound of formula I wherein R is and alkylating the NH 9 group R to give a compound of formula I wherein R is N (alkyl) 9; or 7 Δ the N1 group R is converted by reaction with iodoacetonites-5 rill or bromoacetonitrile in the presence of a suitable base to NHfCl2N).

In the above process step a, the starting material is reacted in a suitable organic solvent such as toluene or DMF or mixtures thereof using a catalyst such as a mineral, carboxylic or sulfonic acid at a temperature between 0 ° C and the boiling point of the solvent, boronic acid. , such as phenylboronic acid, or a ketone, such as acetone, or a ketal, such as 2,2-dimethoxypropane, or an acetal, such as benzal-dehydydimethylacetal, optionally with the addition of a water scavenger, such as a 4A molecular sieve, to give the corresponding compound in which 7- and the 9-position oxygen atoms are joined together by a bond of formula III. The resulting compound is isolated by filtration and removal of the solvent and crystallized from an organic solvent such as petroleum ether. The hydroxy group in the 10-position of the obtained compound is then glycosidated by the above-mentioned method bx or protected by the above-mentioned method b2.

Protection of the hydroxy group at the 25-position by method b2 can be accomplished by acylation with a carboxylic acid anhydride such as acetic anhydride, trifluoroacetic anhydride or in phenylcarboxylic acid anhydride with a suitable solvent such as tricarboxylic acid anhydride or carboxylic acid anhydride or carboxylic acid halide. in mixtures, at a temperature between -40 ° C and the boiling point of the solvent, and in the presence of a base, such as triethylamine or pyridine, to give 6 the corresponding compound in which the oxygen atoms of the 7- and 9-positions are joined by a formula of formula III with an acyl or trimethylsilyl attached to the 10-position oxygen atom.

Protection of the 10-hydroxy group with a tetrahydropyranyl group (Method b2) can be accomplished by reacting the compound obtained in step a with 3,4-dihydro-2H-pyran in a suitable organic solvent such as chloroform, dichloromethane, DMF or in toluene, in the presence of a catalyst such as para-toluenesulfonic acid, and a desiccant such as a 4A molecular sieve at a temperature between -30 ° C and the boiling point of the solvent to give the corresponding compound in which the 7- and 9-position oxygen atoms are joined with a bond of formula III and a tetrahydropyranyl group attached to the 10-position oxygen atom.

In process bx, the compound obtained in step a is reacted with a compound of formula V or VI. In these

the protected hydroxy group R ° or R, respectively

20 may be aliphatic acyloxy (C1-C8), benzoyloxy or substituted benzoyloxy such as para-nitrobenzoyloxy, alkyloxy (C1-C8), allyloxy, benzyloxy or substituted benzyloxy. The substituted benzyloxy group R in the compound of formula V may be, for example, para-nitrobenzoyloxy. The reaction is carried out using an organic solvent such as chloroform, dichloromethane, toluene, ether, DMF, acetone, acetonitrile or nitromethane or mixtures thereof, a catalyst such as para-toluenesulfonic acid or trifluoromethanesulfonic acid trialkylsilyl ester.

optionally an acid scavenger and a desiccant such as a Molecular sieve at a reaction temperature of -70 ° C to + 30 ° C under an inert gas atmosphere such as nitrogen or argon to give the corresponding compound in which the oxygen atoms of the 7- and 35-positions are linked III

il 90777 7 and the 10-position oxygen atom is joined by a structure of formula II in which the symbols

fi Q

R to R are as defined above except for hydroxy, NH2, NH (CH2CN) and NH (CH2CN).

In process step c, deprotection (structure III) of the 7- and 9-positions of the compound obtained in step ba or b2, respectively. Deprotection can be accomplished by reacting this compound in a suitable organic solvent such as chloroform, dichloromethane, DMF in toluene or methanol with dilute aqueous solutions of a catalyst such as carboxylic acid or para-toluenesulfonic acid, and optionally a diol such as 2-methyl- With 2,4-pentanediol at a temperature between 0 ° C and the boiling point of the solvent to give a co-dyste having a free hydroxy group at the 7- and 9-positions.

Method step d, i.e. Glycosidation of the 7-position with a compound of formula V or VI can be carried out under the conditions described above for process step ba. This glycosidation can also be performed by a reaction of formula VI

With a compound according to claim 20, wherein R®1 is acyloxy, alkyloxy, allyloxy or benzyloxy and R is acyloxy, alkyloxy, allyloxy, benzyloxy, NH-acyl or N (alkyl) 2, in an organic solvent such as chloroform, dichloromethane, toluene , in the presence of ether, acetone and aceto-nitrile or mixtures thereof under N-iodosuccinimide and optionally with a desiccant such as a molecular sieve at a temperature between -40 ° C and +40 ° C under a shielding gas atmosphere such as nitrogen or argon,

O

to give a compound wherein R is iodine.

In process step e, the acyl or tetrahydropyranyl group can be selectively removed from the 10-position in carbohydrate chemistry under ordinary conditions in a manner known per se by inorganic or organic bases such as alkali metal or alkaline earth metal hydroxides, sodium carbonate, sodium carbonate and triethylamine in a solvent such as In THF or mixtures of these to give the corresponding compound wherein 4 R is hydrogen. The trimethylsilyl group is removed by reaction with tetrabutylammonium fluoride in an organic solvent such as THF, diethyl ether, dioxane or mixtures thereof at temperatures between -40 ° C and the boiling point of the solvent.

Method step f, i.e. the 10-position of the compound obtained in step e is glycosidized as described above for process step bj.

The deprotection of the hydroxy group in process step g can be carried out in the same manner as described above for the deprotection of the acyl or tetrahydropyranyl group in step e.

7

The resulting compound of formula I wherein R is NH-acyl can be converted, if desired, to a compound of formula I wherein R is N1 by removing the acyl group as described in connection with process step e. Further, a compound of formula I wherein R is NR- may be converted to a compound of formula I wherein R is N (alkyl-2 '> 2 * under reductive amination conditions known per se, or may be converted to a compound of formula I For a reaction in which R is a group NH 4 Cl (CN), by reaction with iodoacetonitrile or bromoacetonitrile in a suitable solvent, for example dimethylformamide, in the presence of a suitable base such as triethylamine.

7

Compounds of formula I in which R is N 1, N (alkyl> 2 (C 1 -C 8) or NH 1 Cl 2 CN) may be converted into salts with an inorganic or organic acid.

The compounds of the formula I or their salts with inorganic acids, such as HCl, or with organic acids, such as glutamic acid or glucuronic acid, can be used as active ingredients in medicaments.

Such a compound can be formulated together with conventional pharmaceutical preparations and / or diluents into a drug which can be used in particular in the treatment of cancer.

I) 90777 9

The mode of administration and use is then substantially similar to that used for known anthracyclines, such as adriamycin, daunomycin or aclasinomycin.

Medicaments prepared in this way may additionally contain other wetting agents, provided that these, together with the compounds prepared according to the invention, do not cause any undesirable side effects.

The cytostatic activity of the compounds of the invention was studied using mouse L1210 leukemia cells. For this purpose, colony formation of L1210 leukemia cells was monitored on agar plates. The purpose of this method is to demonstrate the effect of test substances on the growth behavior of cells after incubation for one hour or several generations. With a cell cycle time of 10 to 12 hours, approximately 14 consecutive generations were observed over a 7-day trial period. The cytostatic agents prepared according to the invention provide a reduction in the number of colonies observed in this experiment compared to the untreated control. The details of the experimental method are shown in the following procedure for determining colony formation.

Procedure for determining the colony formation of L1210 leukemia cells on soft agar 500 leukemia cells per plate were incubated with different concentrations of test substance for one hour at 37 ° C. The cells were then washed twice with McCoy5A-30 medium and finally poured into petri dishes after the addition of 0.3% agar. Control samples were incubated with fresh medium only. Instead of incubating for one hour, in many cases different concentrations and test substances were mixed into the upper agar layer to achieve continuous exposure of the cells throughout the incubation period. After the solidified agar, the plates were incubated in an oven for 7 days at 37 ° C (5% v / v CO 2, 95% relative humidity). The number of colonies larger than 60 μm in diameter was then counted. 5 Results were expressed as the number of colonies in treated agar plates as a percentage of the number of colonies in untreated control experiments. The dose-response curve thus obtained gave an IC50 value as a measure of the potency of the substance. The results for the compounds of formula I tested compared to 10 adriamycin are summarized in Table 1 below.

table 1

Substance No. Duration incubation 1 hour incubation (example) IC50 (pm / ml) IC50 (pm / ml) 15 _

Adriamycin 0.02 0.04 10 0.9 6.5 11 0.5> 1 14 0.004 0.02 20 15 0.006 0.02 16 0.004 0.09 23> 10> 1 24 0.5> 1 26> 1 > 1 25 27 0.026 0.09 29> 1> 1 31 0.85> 1 32 0.29 33 0.11 30 35 0.095 36> 1 37 0.1 38 0.4 0.68 39 0.66 35 40 0.04 0.05 li 90777 11

examples

The structures of the prepared compounds were elucidated by XH and 13C spectroscopy using two-dimensional NMR methods and other multi-pulse methods as well as MS and IR spectroscopy. The progress of the reactions as well as the resulting compounds were studied by thin layer chromatography or HPLC.

The following examples further illustrate the process of the invention 10 for the preparation of compounds of formula I and the preparation of starting materials and intermediates used in the process. For the substituents of the starting materials and intermediates, the names of the compounds refer to the following formula (Iv) 15 H 0 HO OR41 (Iy) 20 ^ 21 OH 0 HO OR 1 and the substituents present therein.

Example 1 7,9-O-Phenylboronyl-β-rhodomycinone (1) 25 (Compound of Formula Iv wherein R 41 = H, R 21 and R 31 = X = phenylboronyl)

A solution of β-rhodomycinone (740 mg = 192 mmol) and phenylboronic acid (360 mg * 2.95 mmol) in toluene (150 mL) was heated with an activated 4A-Mole-30 sieve (3 g) for 9 hours at reflux. in which the reaction was monitored by thin layer chromatography (eluent: toluene / methanol = 10: 1).

After cooling, the solution was filtered and the solvent was distilled off under high vacuum. The precipitate was dissolved in chloroform 35 and crystallized from petroleum ether.

Yield: 800 mg (1.7 mmol = 88%) 12

Example 2 7.9- O-Isopropylidene-B-rhodomycinone (2) (Compound of Formula Iv wherein R41 = H, R21 and R31 * X = isopropylidene) To a solution containing B-rhodomycinone (300 mg = 0.78 nunol) In 30 ml of dry N, N-dimethylformamide (130 ml) and 2,2-dimethoxypropane (36 ml), para-toluenesulphonic acid (150 mg) was added and the mixture was stirred for 60 hours at 50 ° C and 320 mbar. pressure on a rotary evaporator-10 m, adding more 2,2-dimethoxypropane (35 ml). After evaporation of the solution, the residue was taken up in dichloromethane, shaken with aqueous sodium hydrogen carbonate solution, dried and evaporated. After column chromatographic separation (eluent: chloroform / aceto-15 / acetic acid / water / triethylamine = 95: 5: 1: 0.25: 0.1) the product was obtained as crystals.

Yield: 150 mg (0.35 mmol = 45%)

Example 3 7.9-O-Benzylidene-B-rhodomycinone (3) 20 (Compound of Formula Iv wherein R41 = H, R21 and R31 = X = benzylidene)

To a solution of β-rhodomycinone (30 mg = 0.08 mmol) in a mixture of dry N, N-dimethylformamide (5 mL) and benzaldehyde dimethyl acetal (2 mL) was added para-toluenesulfonic acid (10 mg) and the mixture was stirred for one hour. at 50 ° C and 50 mbar on a rotary evaporator. After evaporation of the solution, the residue was taken up in dichloromethane, shaken with aqueous sodium hydrogen carbonate solution, dried and evaporated.

Yield: 35 mg (0.07 mmol = 90%)

The two exo / endo isomers can be separated chromatographically (eluent: toluene / methanol = 10: 1).

90777 13

Example 4 10-O-Trifluoroacetyl-β-rhodomycinone (4) (Compound of Formula IT wherein R 21 = R 31 = H, R 41 = trifluoroacetyl) To a solution containing 7,9-O-phenylboronyl-β-rhodomycinone (Compound 1 ) (230 mg = 0.49 mmol) in dry dichloromethane (50 ml), trifluoroacetic anhydride (4 ml = 283 mmol) and triethylamine (0.2 ml) were added at 0 ° C and the mixture was stirred for 30 minutes at 0 ° C. C.

After evaporation of the solvent and evaporation with toluene several times, the residue was dissolved in methanol and the solution was adjusted to pH 2.5 with hydrochloric acid, whereupon the product precipitated after stirring for 4 hours. The precipitate was dissolved in dichloromethane, washed with water and, after drying, the organic phase was evaporated.

Yield: 150 mg (0.31 mmol = 63%)

Example 5 10-Tetrahydropyranyl-β-rhodomycinone (5) 20 (Compound of Formula I wherein R21 = R31 = H, R41 = tetrahydropyranyl)

To a solution of 7,9-O-phenylboronyl-β-rhodomycinone (500 mg = 1.06 mmol) and 3,4-dihydro-2H-pyran (2.5 mL) in dry dichloromethane (125 mL) was added A 4A molecular sieve was added, a catalytic amount of para-toluenesulfonic acid (20 mg) was added and the mixture was stirred for 1/5 hour at room temperature. The molecular sieve was separated by filtration, after which the filtrate was washed with aqueous sodium hydrogencarbonate solution, dried over sodium sulfate, and the solvent was distilled off.

The crude product was dried under high vacuum and then added to a solution of 2-methyl-2,4-pentanediol (5 ml) in dry dichloromethane (40 ml) and the mixture was stirred with a catalytic amount of glacial acetic acid 35 (0.2 ml) for 48 hours. at room temperature.

14 It was then shaken with aqueous sodium hydrogencarbonate solution and water and dried over sodium sulfate. Column chromatographic separation (eluent: toluene / methanol = 10: 1) gave pure product.

5 Yield: 210 mg (0.45 mmol = 42%)

Example 6 10-O-Trimethylsilyl-β-rhodomycinone (6) (Compound of Formula Iv wherein R 21 = R 31 = H, R 41 = trimethylsilyl) To a solution containing 7,9-O-phenylboronyl-β-rhodomycinone (100 mg 0.21 mmol) and pyridine (85 μl) in dry dichloromethane and a 4A molecular sieve, trifluoromethanesulfonic acid trimethylsilyl ester (110 μΐ) was added at -40 ° C and the mixture was stirred for 1.5 hours. The reaction mixture was filtered, shaken with aqueous sodium hydrogen carbonate solution, dried over sodium sulfate and evaporated.

The crude product was dissolved in dry dichloromethane (10 ml) to cleave the boronyl ether, 2-methyl-2,4-pentanediol (0.55 ml) and glacial acetic acid (0.1 ml) were added and the mixture was stirred for 48 hours at room temperature. . The reaction mixture was shaken with water, dried over sodium sulfate, evaporated and separated by column chromatography (eluent: dichloromethane / acetic acid / formic acid = 20: 1: 0.1).

Yield: 57 mg (0.11 mmol * 52%)

Example 7 10-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -7,9-O-phenylboronyl-β-rhodomycinone 30 (7) (Compound of Formula I „ where R21 and R31 = phenylboronyl, R41 * structure II * αL-acosaminyl where R6 = OpNBz, R7 = NHTFA and R8 = H)

To a solution of 7,9-O-phenylboronyl-B-35 rhodomycinone (Compound 1) (100 mg = 0.21 mmol) in a dry

II

90777 in dichloromethane (8 ml) and a 4A molecular sieve, a solution of 1,5-anhydro-4-O-para-nitrobenzoyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-arabinohexane was added. - 1-enite (87 mg = 0.23 mmol) in dry dichloromethane 5 (4 ml), and trifluoromethanesulfonic acid trimethylsilyl ester (40 μΐ = 0.22 mmol) was added at -40 ° C under an inert gas atmosphere (argon). ). After warming to -20 ° C, the mixture was stirred for a further 4 hours at this temperature and then quenched by the addition of triethylamine (80 μΐ). After filtration, the solution was washed with aqueous sodium hydrogencarbonate solution, dried over sodium sulfate, evaporated and distilled several times with toluene.

Yield of crude product: 180 mg (quantitative yield).

Example 8 10-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -8-rhodomycinone (8) (Compound of Formula IT wherein R21 = R31 = H, R41 = structure II = αL-acosaminyl where R6 = OpNBz, R7 = NHTFA and R8 = H)

A solution of a crude mixture of compound 7 (180 mg = 0.21 mmol) in dry dichloromethane (20 mL) was stirred with 2-methyl-2,4-pentanediol (3.2 mL) and glacial acetic acid (0.2 mL). with 24 hours at room temperature.

For further work-up, the mixture was distilled several times with toluene and 150 mg of a crude product were crystallized from diethyl ether / petroleum ether, which was purified by column chromatography (eluent: dichloromethane / acetone / formic acid = 20: 1: 0.2).

Yield: 120 mg (0.16 mmol = 75%)

Example 9 10-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-αL-daunosaminyl) -8-rhodomycinone (9) 35 A compound of formula Iv wherein R21 = R31 * H, R41 16 = structure II = α-L-daunosaminyl, where R6 = OpNBz, R7 = NHTFA and R8 = H)

Following the procedure of Example 7, 7,9-O-phenylboronyl-β-rhodomycinone (Compound 1) (150 mg = 0.318 mmol) and 1,4-di-O-para-nitrobenzoyl-3-N-trifluoroacetyl-L -daunosamine (190 mg = 0.35 mmol) to react with trifluoromethanesulfonic acid trimethylsilyl ether (0.11 mL = 0.61 mmol).

The resulting crude product was deprotected to cleave the boronic acid ester according to the instructions of Example 8.

Yield: 180 mg (0.24 mmol = 75%)

Example 10 10-O-αL-Acosaminyl-β-rhodomycinone (10) A compound of formula I wherein R 2 = H, R 4 = structure II = α-L-acosaminyl wherein R 6 = OH, R 7 = NH 2 and R 8 = H)

A solution of compound 8 (36 mg = 47 μπιοί) in a mixture of methanol (2 ml) and 0.5 N sodium hydroxide solution (2 ml) was stirred for 30 minutes at room temperature and then adjusted to pH with hydrochloric acid. 2.5. It was then shaken several times with chloroform. The aqueous phase was neutralized with sodium hydrogen carbonate solution and shaken several times with chloroform-25. This chloroform phase was dried over sodium sulfate and evaporated.

Yield: 17.5 mg (34 μπιοί = 72%)

Example 11 10-O- (3-N, N-Dimethyl-αL-acosaminyl) -8-rhodomycin-30-non (11) (Compound of formula I wherein R 2 = H, R 4 = structure 11 = α-L-acosaminyl where R5 = CH3, R6 = OH, R7 = N (CH3) 2 and R8 = H)

A solution of compound 10 (23 mg = 42 35 pmol) in methanol (2 ml) is mixed with sodium cyanoborohydride (16 mg = 250 μπιοί) and formaldehyde (63 μΐ, 11 90777 17 37% = 860 μπιοί). 2 hours at room temperature. It is then neutralized with hydrochloric acid and purified by chromatography (eluent: chloroform / methanol / acetic acid / water / triethylamine = 80: 20: 10: 4: 0.2).

5 Yield: 15 mg (28% 67%)

Example 12 7-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -10-O-trifluoroacetyl-β-rhodomycinone (12) 10 A compound of formula Iv wherein R 31 = H, R41 = trifluoroacetyl, R21 = structure II = αL-acosaminyl, where R6 = OpNBz, R7 = NHTFA and R8 = H)

Compound 4 (90 mg = 0.19 mmol) was reacted under the conditions described in Example 7. Yield of crude product 15: 150 mg (0.18 mmol = 95%).

Example 13 7-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -5-rhodomycinone (13) (Compound of Formula IT wherein R31 = R41 = H, R2120 = structure II = α-L-acosaminyl, where R6 = OpNBz, R7 = NHTFA and R8 = H)

A solution of compound 12 (100 mg = 0.12 mmol) in methanol (5 mL) was adjusted to pH 10 with 0.1 N sodium hydroxide solution and stirred for 10 minutes.

The reaction mixture was neutralized with dilute hydrochloric acid, and the solvent was distilled off. The residue was taken up in dichloromethane, washed with water, dried over sodium sulfate and evaporated.

Yield of crude product: 85 mg (0.11 mmol = 92%) Example 14 7-O-αL-Acosaminyl-e-rhodomycinone (14) (Compound of formula I wherein R 4 * H, R 2 * structure II = α-L -acosaminyl in which R 6 * OH, R 7 - NH 2 and R 8 - H) 35 Under the conditions described in Example 10 18 was deprotected from compound 13 (27 mg = 35 μιηοΐ) and the product was worked up.

Yield: 15 mg (29 μmol = 83%)

Example 15 7-O- (3-N, N-Dimethyl-αL-acosaminyl) -β-rhodomycinone (15) (Compound of formula I wherein R 4 = H, R 2 = structure II = αL-acosaminyl wherein R6 = OH, R7 = N (CH3) 2 and R® = H) Compound 14 (15 mg = 29 pmol) was reacted according to the conditions of Example 11.

Yield: 13 mg (24 pmol * 83%).

Example 16 7-O- (3-N-Cyanomethyl-αL-daunosaminyl) -β-Rhodo-15 mysinone (16) (Compound of formula I wherein R 4 = H, R 2 * structure II = αL-daunosaminyl where R 6 = OH, R 7 = NH (CH 2 CN) and R 8 * H) 7-O-αL-daunosaminyl-β-rhodomycinone (200 mg = 0.39 mmol) was dissolved in dry N, N-dimethylformamide (30 mL), and after triethylamine (0.16 ml) and iodoacetonitrile (0.283 ml) were added thereto, followed by stirring at room temperature for 15 hours. The reaction mixture was then evaporated under high vacuum and purified by column chromatography using 50 g of silica gel (eluent: dichloromethane / acetone / acetic acid * 5: 2: 1). Yield: 157 mg (0.28 mmol = 73%); MS: M + H &lt; + &gt; = 555

Example 17 7-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-1H-αL-daunosaminyl) -10-O-trifluoroacetyl-β-rhodomycinone (17) (A compound of formula Iv wherein R31 = H, R41 = trifluoroacetyl, R21 * structure II = αL-daunosaminyl where R6 - OpNBz, R7 = NHTFA and R8 * H) 35 10-O-trifluoroacetyl-β-rhodomycinone (500 mg = li 90777 19 1.03 mmol) was dissolved in a mixture of dichloromethane and acetone (1: 1; 40 ml). To the solution were added a molecular sieve (4A, dried powder, 500 mg) and 1,4-di-O-para-nitrobenzoyl-3-N-trifluoroacetyl-ldunosamine 5 (1.1 g to 2.05 mmol) and cooled to -30 ° C while preventing access to humidity. Trifluoromethanesulfonic acid trimethylsilyl ester (0.9 mL = 5.15 mmol) was added dropwise to the suspension with stirring. After 2 hours, triethylamine 10 (0.8 mL) was added. The mixture was filtered at room temperature and the filtrate was washed three times with ice water. The organic phase was dried over sodium sulfate and evaporated in a vacuum with a water jet pump. The crude product obtained was purified by column chromatography (silica gel 60 / 35-70, trade name Amicon, eluent: dichloromethane / petroleum ether / acetone = 5: 5: 1).

Yield: 750 mg (0.88 mmol - 85%)

Example 18 7-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-20β-αL-daunosaminyl) -β-rhodomycinone (18) (Compound of Formula Iv wherein R 31 = R 41 = H, R 21 = structure II = α-L-daunosaminyl, where R6 = OpNBz, R7 = NHTFA and R8 = H)

Compound 17 (660 mg = 0.77 mmol) was dissolved in 25 ml of a 1: 1 mixture of chloroform and methanol. Aqueous 0.01 N sodium hydroxide (30 mL) (pH 7.5) was then added dropwise. After 3 hours, the solution was neutralized with 0.1 N aqueous hydrochloric acid and evaporated in vacuo. The product was purified by thin layer chromatography using column chromatography using 200 g of silica gel 60 / 35-70, trade name Amicon (eluent: dichloromethane / acetone = 15: 1 to 5: 1). Yield: 570 mg (75 mmol * 97%).

20

Example 19 7-O- (3,4-Di-O-acetyl-2,6-dideoxy-2-iodo-α-thalopyranosyl) -10-O-tetrahydropyranyl-β-rhodomycinone (19) 5 (Compound of Formula Iv where R31 = H, R21 = structure II = 2,6-dideoxy-αL-talopyranosyl, where R6 = R7 = OAc and R8 = I; R41 tetrahydropyranyl)

To a solution of compound 5 (30 mg = 0.06 mmol) and 3,4-di-O-acetyl-1,5-anhydro-2,6-dideoxy-L-10 lyxohex-1-enite (26 mg = 0.12 mmol) in 3 mL of dry acetonitrile and an activated 3A molecular sieve, N-iodosuccinimide (36 mg · 0.16 mmol) was added under an inert gas atmosphere (argon) at -10 ° C and at a reaction time of 4 days. was raised to room temperature. After filtration, it was diluted with dichloromethane and the organic phase was shaken first with aqueous sodium thiosulphate solution, then with sodium hydrogen carbonate solution and then with water, dried and purified by chromatography (eluent: toluene / methanol-10: 1).

Non-optimized yield: 10 mg (0.013 mmol = 20%)

Example 20 7-O- (3,4-Di-O-acetyl-2,6-dideoxy-2-iodo-αL-mannopyranosyl] -10-O-tetrahydropyranyl-f-rhodomycinone 25 (20) (Compound of Formula Iv where R31 = H, R21 = structure II = 2,6-dideoxy-αL-mannopyranosyl where R6 = R7 = OAc and R8 = I; R41 tetrahydropyranyl) Compound 5 (70 mg = 0.15 mmol) was reacted according to Example 19. 30 with 3,4-di-O-acetyl-1,5-anhydro-2,6-dideoxy-L-arabinohex-1-enite and the product was worked up.

Non-optimized yield: 45 mg (0.056 mmol = 37%).

90777 21

Example 21 7-O- (3,4-Di-O-acetyl-2,6-dideoxy-2-iodo-αL-mannopyranosyl) -β-rhodomycinone (21) (Compound of formula I wherein R 31 = R 41 « H, R21 5 = structure II = 2,6-dideoxy-αL-mannopyranosyl, where R6 * R7 OAc and R8 * I)

To a solution of 20 (34 mg = 0.04 mmol) in 2 mL of methanol was added an acidic ion exchanger (Dowex 50 WX8) and the mixture was stirred for 24 hours. After filtration of the ion-10 exchanger, it was purified by chromatography (eluent: dichloromethane / acetone / formic acid = 20: 1: 0.1).

Non-optimized yield: 13 mg (0.018 mmol = 45%)

Example 22 7,10-Di-O- (4-O-para-nitrobenzoyl-3-N-trifluoroacetyl-αL-daunosaminyl) -β-rhodomycinone (22) (Compound of formula wherein R31 * H, R21 = R41 - structure II = αL-daunosaminyl where R6 = OpNBz, R7 = NHTFA and R8 = H)

Compound 9 was reacted according to Example 7 with 1,4-di-O-para-nitrobenzoyl-3-N-trifluoroacetyl-L-daunosamine and trifluoromethanesulfonic acid trimethylsilyl ester and the product was worked up.

Example 23 7.10-Di-O-α-L-daunosaminyl-β-rhodomycinone (23) 25 (Compound of formula I wherein R 2 = R 4 * structure II = α-L-daunosaminyl where R 6 = OH, R 7 = NH 2 and R 8 = H)

Compound 22 was deprotected under the conditions described for compound 10 and the product was worked up.

Example 24 7.10-O-Di- (3-N-cyanomethyl-αL-daunosaminyl) -β-rhodomycinone (24) (Compound of formula I wherein R 2 = R 4 = structure II = α-L-daunosaminyl where R 6 = OH, R7 = NH (CH2CN) and R8 = H)

The title compound was prepared starting from compound 23 (132 mg = 0.2 mmol) and iodoacetonitrile (0.15 mL) according to the procedure described in Example 16 above.

Yield: 76.6 mg (0.11 mmol = 53%). MS: M + H + = 723 Example 25 7.10-Di-O- (4-O-para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -β-rhodomycinone (25) (Compound of Formula Iv where R31 (H, R21 = R41 = structure II = α-L-acosaminyl where R6 = OpNBz, R7 = 10 NHTFA and R8 = H)

Compound 8 was reacted according to Example 7 and the product was worked up.

Example 26 7.10-Di-O-αL-acosaminyl-S-rhodomycinone (26) 15 A compound of formula I wherein R 2 = R 4 = structure II = α-L-acosaminyl where R 6 = OH, R 7 = NH 2 and Rfl = B)

Compound 25 was deprotected according to the conditions described for compound 10.

Example 27 7,10-di-O- (3-N, N-dimethyl-α-L-acosaminyl) -B-ro-. domycinone (27) (Compound of formula I wherein R 2 = R 4 = structure II where R 6 = OH, R 7 = N (CH 3) 2 and R 8 = H)

Compound 26 was reacted according to the conditions of Example 11.

Example 28 7-O- (4-O-Para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -10-O- (4-O-para-nitrobenzoyl-3-N-trifluoroacetyl-αL-daunosaminyl ) -β-rhodomycinone (28) 30 A compound of formula Iw wherein R31 = H, R21 = structure II * α-L-acosaminyl where R6 = OpNBz, R7 NHTFA and R8 = H? R41 = structure II = aL- daunosaminyl where R6 = OpNBz, R7 = NHTFA and R8 - H)

Compound 9 was reacted according to Example 7 and the product was worked up.

Il 90777 23

Example 29 7-O-αL-Acosaminyl-10-O-αL-daunosaminyl-β-romomycinone (29) (Compound of formula I wherein R 2 = structure II = 5 αL-acosaminyl wherein R 6 «OH, R 7 * NH2 and R8 = H; R4 = structure II * α-L-daunosaminyl, where R6 = OH, R7 = NH2 and R8 = H)

Compound 28 was deprotected under the conditions described for compound 10 and the product 10 was finished.

Example 30 7-O- (4-O-Benzoyl-αL-rhodosaminyl) -10-O- (4-O-para-nitrobenzoyl-3-N-trifluoroacetyl-αL-acosaminyl) -β-rhodomycinone (30) (A compound of formula Iv wherein R 31 * H, R 21 «structure II» α-L-rhodosaminyl wherein R 6 OBz, R 7 = N (CH 3) 2 and R 8 = H; R 4 * structure II = α-L-acosaminyl wherein R 6 = OpNB 2, R 7 = NHTFA and R 8 = H) 7-O- (4-O-benzoyl-αL-rhodosaminyl) -β-rhodomycin-20 was reacted according to Example 7 and the product was worked up.

Example 31 10-O-αL-Acosaminyl-7-O-αL-rhodosaminyl-β-rhodomycinone (31) 25 A compound of formula I wherein R 2 * is structure II - α-L-rhodosaminyl wherein R 6 * OH, R 7 = N (CH3) 2 and R8 = H; R4 = structure II = α-L-acosaminyl, where R6 = OH, R7 = NH2 and R8 = H)

Compound 30 was deprotected under the conditions described for compound 10 and the product was worked up.

Example 32 7-O- (3-N-Trifluoroacetyl-αL-acosaminyl) -β-rhodomycinone (32) 35 A compound of formula I wherein R 4 is H; R 2 = structure II = α-L-acosaminyl wherein R6 = OH, R7 = NHTFA and R® = H)

A solution of compound 12 (27 mg = 32 pmol) in a mixture of dry methanol (2 ml) and 2 drops of methanolic sodium methanolate solution (33%) was stirred for 1 hour at room temperature, neutralized with an acidic ion exchanger (Dowex WX8). , filtered, evaporated and purified by chromatography (eluent: dichloromethane / methanol / formic acid 10: 1: 0.2). Yield: 15 mg (25 mmol = 78%)

Example 33 7-O-αL-Crossosaminyl-β-rhodomycinone (33) (Compound of Formula I wherein R 4 = H, R 2 = Structure II = αL-crossosaminyl where R 6 = OH, R 7 = NH 2 and R 10 = H )

Compound 4 was reacted under the conditions described in Example 7 with 1,5-anhydro-4-O-para-nitrobenzoyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-ribohex-1-enite. and deprotection under the conditions set forth in Example 20. Melting point: 217 ° C. MS: M + H &lt; + &gt; = 516.

Example 34 7-O- (3-N-Trifluoroacetyl-αL-crossosaminyl) -β-rhodomycinone (34) 25 A compound of formula I wherein R 4 = H, R 2 = structure II = α-L-crossosaminyl wherein R® * OH, R7 = NHTFA and R® * H)

Compound 4 was reacted under the conditions described in Example 7 with 1,5-anhydro-4-O-para-nitro-30-benzoyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-ribohex-1-enite. and deprotection under the conditions set forth in Example 32. Melting point: 178 ° C. MS: M + H &lt; + &gt; = 612.

Il (35) 25 90777

Example 35 7-O- (4-O-Benzyl-αL-acosaminyl) -β-rhodomycinone (Compound of Formula I wherein R 4 = H, R 2 = ra-5 Formula II = αL-acosaminyl where R 6 = OBn, R 7 = NH2 and R8 = H)

Compound 4 was reacted with 1,5-anhydro-4-O-benzyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-arabino-hex-1-10 enite under the conditions described in Example 7 and deprotected in Example 7. 10 under the conditions set forth. MS: M + H &lt; + &gt; = 506.

Example 36 7-O- (4-O-Benzyl-3-N-trifluoroacetyl-αL-acosaminyl) -β-rhodomycinone (36) 15 A compound of formula I wherein R 4 = H, R 2 = structure II = α-L-acosaminyl, where R6 = OBn, R7 = NHTFA and R® = H)

Compound 4 was reacted with 1,5-anhydro-4-O-benzyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-arabinohex-1-enite under the conditions described in Example 7 and deprotected in Example 7. 32 under the conditions set out.

Example 37 7-O- (2,6-Didoxy-2-iodo-αL-mannopyranosyl) -β-25 rhodomycinone (37) (Compound of Formula I wherein R 4 = H, R 2 = Structure II - 2,6-Didoxy) -L-mannopyranosyl where R6 = OH, R7 = OH and, R® = I)

Compound 21 was dissolved in a mixture of dry methanol and 2 drops of sodium methanolate solution (33%), stirred for 2 hours at room temperature, neutralized with an acidic ion exchanger (Dowex WX8), filtered and evaporated. Melting point: 158 ° C.

26

Example 38 7,10-Di-O- (4-O-benzyl-αL-acosaminyl) -β-Rhodomycinone (38) (Compound of Formula I wherein R 2 = R 4 = Structure 5 II = α-L-Acosaminyl where R® = OBn, R7 = NH2 and R® = H)

Compound 1 was reacted according to Example 7 with 1,5-anhydro-4-O-benzyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-hex-1-enite, followed by deprotection according to Example 8. and Gly-10 was re-cosidized according to Example 7 with 1,5-anhydro-4-O-benzyl-2,3,6-tridesoxy-3-N-trifluoroacetyl-L-hex-1-enite and deprotected according to Example 10. MS: M + H &lt; + &gt; = 826.

Example 39 7-O- (4-Deoxy-3-N-trifluoroacetyl-αL-daunosaminyl) -β-rhodomycinone (39) (Compound of formula I wherein R 2 = R 4 = structure 11 = α-L- daunosaminyl where R6 = H, R7 = NHTFA and R® = H)

Compound 4 was reacted with 1-O-para-nitrobenzoyl-4-deoxy-3-N-trifluoroacetyl-L-daunosamine under the conditions set forth in Example 7 and deprotected under the conditions set forth in Example 32.

Example 40 7-O- (4-Deoxy-αL-daunosaminyl) -β-rhodomycinone 25 (40) (Compound of formula I wherein R 2 = R 4 = structure II = α-L-daunosaminyl where R 6 = H, R 7 = NH2 and R® = H)

Compound 4 was reacted with 1-O-para-nitrobenzoyl-4-deoxy-3-N-trifluoroacetyl-L-daunosamine under the conditions set forth in Example 7 and deprotected under the conditions set forth in Example 10.

Tables 2 and 3 below summarize the 1-39 1 NMR data of some of the new compounds listed above.

li

Table 2 27 90777

1 H-NMR data of compounds of formula I and intermediates formed in their preparation

The substance numbers in the first line correspond to the example numbers in question. The chemical shift is reported in parts per million, with tetramethylsilane acting as the internal standard. Unless otherwise indicated, the spectrum was measured in CDCl 3 as a solvent.

Abbreviations: s: singlet d: doublet 15 t: triplet q: quartet m: multiplet dd: doublet of doublet ddd: doublet of doublet 20 dq: doublet of quartet a) measured at 300 mHz b) B-phenyl 7.4 to 7.27 mc) measured at 270 MHz d) Compounds 3a and 3b are exo-endo isomers 25 e) benzylidene-CH 5.41 s, aromatic benzylidene 7.36-7.20 mf) benzylidene-CH 6.13 s, aromatic benzylidene 7.36 - 7.17 mg) tetrahydropyranyl ring H1 4.91 m and 4.99 30 m, ring protons 4.0-3.1 m because the substance exists as a mixture of diastereomers (R / S at THP ring Cl ), some signals are doubled h) measured at 400 mHz 35 i) O-trimethylsilyl 0.13 s 28 k) B-phenyl 7.35 - 7.17 m

l) solvent CDCl 3 + CD 3 OD

m) solvent CDCl 3 + d 6 -DMSO

n) N (CH 3) 2 2.086 s 5 o) tetrahydropyranyl H-1 5.09 dd, OAc 2.03 s, 2.09 s p) tetrahydropyranyl H-1 5.04 dd; ring protons 4.2 - 3.0 m, OAc 2.03 s, 2.01 sq) OAc 2.04 s, 2.01 s 10 s) measured at 200 MHz t) benzyl CH 2 4.77 d, 4 , 66 d, aroma. Benzyl 7.37 m u) benzyl CH 2 4.46 d, 4.33 d, aromat. benzyl 7.29 - 7.12 m 15 v) measured at 90 MHz

Table 2 - Part 1 90777 29 η a, b) 2c) 3aa, de) 3ba, d'f ^ H-1 7.90 ^ dd 7. 8 2 1 d 7; 35dd 7.82dd H - 2 7, 6 9 S r, 6 4 5 t 7. 6 "t ~. 6 4: H-5 7,774dd 7 f 2 6 2 d 7f29dd 7.23dd H-7 5,672: S, 279t 5; 67dd 5.54t H-Sa 2, 2 9 5 dd 2" 39dd 2 , 51dd 2.67dd H-8b 2119dd 2.15dd 1.79dd 2.16dd H-1 0 4.97 3d 4; 782d 4.94d 4, 84d H-13a 2, 22 - 1, 79m 1T95m 1.98-1, Tim 1.99-1.89m H -1 3 'o 2, 22 - 1.79m 1.76m 1, 98-1 f 71 m 1.99-1; 89n H-- 14 T, 236r 1, 0481 1 , 07: 1,11: H -1 '- - - - H-2a' - - - H-2e '- - - H - 3' - - H-4 '- - H-5' - - H.- 6 '- - - OH-4 12,145s 12,151s 12.09s 11.96s OH - 6 1 2,785 1 2 r 6 S 3 s 12.67s 1 2.66 s OH-11 1 3, 5 7 5 s 13,498s 13.70s 15.51s OH-7 - - OH-9 - - H -1 0 2.6 8 d 3, 18d 2.80d NHTFA - - pNB: 30

Table 2 - part 2 4a) sc »g) 6h, i) 7a-k) H -1 7, 90 2 dd 7.7Sd 7.391dd 7.7 ~ d H-: 7.745: 7. 64t 7, 71 5t 7, 5 99: H-5 7; 54 7dd 7.24d 7.312dd ", ~ 0dd H - '5, 34 5 dt 5.19dd /' 5.14dd 5 7 2 3 1 t 5,680 H - 8 a 2, 4 OSdt 2.30dd 2.22Sdd 2, 45dd H-Sb 2.0 5 4 ddd 2.0 5 d 2.146dt 2.18d H-10 6f 544d 4.945 / 4.8 1 5 4; 8 2 2d 4 f 9 5 6 s H-15a 1f75m 1.75m 1.718m 1 .85m H-15b l, 56m 117 5 m. 1, 713m 1,85m H-- 14 1, 103t 1,03t 1, 075t 1, 1 St H-1 '- - 5? 64d H-2a * - - - 1.83m H-2e '- - - 2.12m H-3' - - - 4.44m H-4 '- - 4.7S61 t H-5' - - 4,18dq H- -6 '- - - 1 - 2 ”do 'OH-4 12,0105 11r97s 12 f106 s 1 2.03 2 s OH-6 1 2,806 s 12,81s 1 2,897s 12% 7l4s OH-11 1 5 T 3 4 5 d 13,66s / 15.6s 1 3 6 2 6 s 1 3 ^ 6 9 4 s OH- '5; 4 5 2d 5; 478d OH-9 3, 7 5 6 s 3.14Ss OH - 10 - NHTrA - 6.45d 6.44d pNB: - 8.2S-8.08m 8.34-8.15m

Table 2 - part 3 31 90777 8C) gh) ΙΟ3.1- * H-1 7.91d d 7.90 5 dd 7.774d H-: 7.731 7.7 26 t "f621t H-3 7.34dd 7.344 dd 7,209d H-7 5.31d 5 f 2 7 91 5 f08 "d H-3a 2 f 36 dd 2.308dd 2f1S4d H-Sb 2 7 2 2d 2.195d 2.06d H-10 4, 98s 5.020s 4 ^ 87s H-13a 1T95-1 T '2m 1; 88-1.38m 1.82m H-13'c 1.95-1, ^ 2 ^ 1, 88-1.33m 1 (82m H-- 14 1. 16t 1, 155t 1 .O 21 J fff H-1 '5.3 "d 5 f 6 5 9 d 5.31d H - 2 a' 1, Sm 2, 16-1 fS9m 1, 49m H-2e '2r09dd 2.16-118 9m 2.09m H-3 '4.4 S d 4.495m 2.87m H-4' 4, 8 21 5.409s 2.87m H-5 '4.21dq 4.314q 3.66dq H - 6 '1 T2Sd 1, 228d 1, 236d OH-4 12 j O6S 12 f 041 s OH-6 12, 89s 12 f 894s OH-11 13 r 72s 1 3 7735s OH-7 5; 54d 3,4 91 d OH- 9 3 f 34 s 3f 248s

OH- 1 O

NHTFA

pNB n · 32

Table 2 - part 4 -h, n) h) h) h, m) 11 12 13 14 H- 1 ", 8 2 1 d 7f908d 7, S00d 7 r 7 8 d H-2 ^, 644t 7, 7 38t 7.6221 '.6-t H- 3 7.24 5 d 7 j 554d 7,: 29d ~, 2 1 d H-7 5.16'd 5.2 461 5 f 063t 4.993 * H-8a 2 ( .2-2.09m 2.40dd 2.24-1.99m 2.105m H-3b 2.2-2.09171 2; 4 5 d 2, .24 -1.99m 2.105m H - 1 0 4,908s 6,414 d 4f854d 4.70s H-13a 1, 85 -1, 66 m 1,7 5m 1,86-1,69m 1,75-1,6Om H - 1 5 b 1 3 3 - 1 6 6 m 1, 75m 1, 8 6 - 1, 6 9 m 1.75-K60m H3-14 1f 05 91 1, 1 251 1, 07 31 0.99t H-1 '5.41'd 5.52 Od 5.41 9 5, 29d H-2 a '1, 489ddd 1} 86ddd 2.24-1.99m 1 (.49m H-2e' 2, 194ddd 2.01ddd 2.24-1, 99m l, 94m H-3 '2 (602ddd 4.3m 4.38m 2.8m H-4 '3.01 21 4. 841 4.89U 2.8m H-3' 3.699dq 4.3m 4.278dq 3.77dq H, -6 '1.2 6 8 d 1 f 3 3 0 d 1 .2 3 8 d 1,23d OH-4 12,002s 12,023s OH-6 12,813s 1 2, 796 s OH-11 13,380s 13 ^ 551 s OH- 'OH-9 3,819 s 3,575 s «t OH-10 - 3,615d NHTFA - 6,4 7d pNBz - 8f 25-8,9m 8,22-8,09m

II

Table 2 - part 5 90777 33 lS *> 1 ^ li "· 1'H-1 7.-9dd 7.74d 7; 70d H- 2 7.6 341 7} 65t 7, 6 21 H-5 7? 2 2 9dd 7,22d 7,17d H-7 5,059dd 5 j 2 5 d 5,06s H-8a 2, 2 2 - 2,0 2m 2,47d 2, 1 3m H-Sb 2,2 2 -2, 02n 2.08dd 2.15m H-10 4, S 5 7 d 6, 53 s 4f78s H-15a 1.90-l752m 1.77m 1.88m H-13 b 1 j 9 0 - 1.5 2 m 1.55m 1 .68m H - - 1 4 1, 0541 1, 1 01 1, 05t H-1 '5.4 7 2 d 5 ^ 6 3 s 5.53s H-2 a' 1.90-1 f52m 1.90ddd H -2e '2.22 -2.02m 2f13m H-3' 2, 5 7 8 ddd 4.48m 4.54m H-4 '3, 101t 5 j 4 9 s 5.42s H-5' 3.8 5 7dq 4.48m 4.44q H.-6 '1. 32 Od 1, 27d 1, 16d OH-4 11 f84s OH-6 12.68s OH-11 13.22s OH-7 - - - OH-9 3,881 s 3.85 s OH-10 NHTFA - 6f61d pNB - 8f25m 8.23m

Table 2 - part 6 34 - 19h. °) 20h.P) 2ia, q) H-1 7, 8 8 d 7; 90d 7; 83d H-2 7,6 91 7, 691 7, 691 H-3 7,50d 7; 51d ", 2Sd H-7 5 T 1 21 3,071 5, 02dd H-Sa 2,22d H-3b 2 , 11dd H - 10 4 j 9 8 s 5.04s 4f88s H- 1 3 a 1.91-1.7 Om H-15b 1, 91-1, 7Om H - 14 1, 13t 1 .17t 1, 1Ot H -1 '5, 79s 5.3 7 s 5 f 71d H- 2 a' - H-2e '4f56dd 4.61dd 4.66dd H-3' 4.2 7 d 4.2 9dd 4, 3 2 dd H -4 '4; 86 s 5r16t 5.18t H-5' 4.08q 4.04dq 4.17dq H - 6 '1.21d 1 .24d 1.29d OH-4 12 γ12 s 12, 12 s 12, 04s OH-6 12.89 s 12.90s 12.79 s OH-11 1 3.78s 13 j 81 s 13 (51 s OH- 7 - OH-9 3.37 s OH -10 - - 2.80s NHTFA - pNBd - I! 35

Table 2 - part 7 90777 - s) - a) a) 32 33 34 Hl 7.80d 7.75dd 7.88d H-2 7.69t 7.64t 7.73t H-3 7; 24d 7.15dd 7, 32d H-7 5.02t 4.87m 4.96d H-8a 2.20m 2.08m H-8b 2 f 20m 2.08m H-10 4f82m 4.60s 4f81s H-13a 1.72ml, 78m H-13b l, 72m 1.78m H3-14 1.06t l, 04t 1f 09t H-1 '5.35d 5.42d 5.35s H-2a' 2120m 2.08m H-2e '2r 20m 2.08m H-3' 3, 80m 3.66m 4.39ddd H-4 '3.16t 3.52dd 3.50dd H-5' 3.96dq 4.14dq 4.15dq H3-6 '1.32d 1j 37d l, 34d 0H-4 12 r 08s 0H-6 12.79s OH-11 13.59s 0H-7 - 0H-9 OH-10 NHTFA 7.75d - 8, Old pNBz -

Table 2 - part 8 36 35 a »t) 36h-u) 37 a) 39'v> Hl 7 T 88d 7 f 86d 7.91dd 7.92dd H-2 7; 72t 7.70t 7.76t 7.71t H-3 7; 32d 7.31d 7.35dd 7.28dd H-7 5.13m 5.24s 5.07d 5.12t H-8a 2.22d 2.37d H-8b 2.16dd 2.10m / * H-10 4 j 91 s 5; 09s 4.81d 4.95d H-13a 1f 9–1.5m 1.98m 1? 7m H-13b 1.9-1.5m lf98rr, 1 f 7m H3-14 l, llt l, 03t 1f 08t l, 13t H-l '5.43d 5 j 27d 5f71s 5.52d H-2a' 2, 2-1.5m 2.10m H-2e '2.2-1r5m 2; 19ddd 4.45dd H-3' 3 ,. 09ddd 3f93m 3.97dd 4.2m H-4 ’2? 911 3.09t H-5 '3 j98dq 3.39dq 4.2m H3-6' 1.41 d 0f98d 1, 38d l, 28d OH-4 12, lls 12,18s 12,14s OH-6 12 f 88s 12 , 93s 12.77s OH-11 13f65s 13.72s 13.52s OH-7 - - OH-9 OH-10 2.68d NHTFA 6 j 09d 5.92d pNBz

II

90777 37

Table 3

1 H-NMR data of the compounds of formula I and the intermediates formed in their preparation

The substance numbers in the first line correspond to the example numbers in question in each case. Chemical shift is expressed in parts per million, with tetramethylsilane acting as an internal standard. Unless otherwise indicated, the spectra were measured in CDCl 3 used as solvent.

10 Abbreviations s: singlet d: doublet t: triplet q: quartet 15 n: multiplet dd: doublet doublet ddd: doublet doublet dq: quartet doublet

Carbohydrate protons with one comma 20 (H-1 ', etc.) denote carbohydrates as radical R2, carbohydrates with carbohydrates (H-1 ", etc.) denoted by single comma denote carbohydrates as radical R4 in general formula I.

a) measured at 270 MHz 25 c) measured at 300 MHz e) measured at 400 MHz f) solvent C0C13 + d6-DMS0 h) solvent D20 i) N (CH3) 2 2.10 s, 2.07 s 30 k) OBz 7.72 - 7.56 m; N (CH 3) 2 2.28 s

Table 3 - Part 1 38 22a) 23S'f) H - 1 7. 7 9 5 d 7. 7 4 d H - 2 7.6 51 t 7.5? * H - 3 7.24 1 d 7. 1 Sd H - 7 5.1 5 71 4.961 H-Sa 2.24 -1 .94m 1 .69-K4Sm H-8b 2.24 - 1. 9 4 t, 1.69-1. 4S: nr.

H-10 5,071s 4,785 H-13a 1 .85 - 1 .66m 1 .69-1 .4Sm H -13 b 1 .35 - 1 .66ai 1 .69-1 .4Sm H - -14 1. 107t 0.92t H -1 '5.431db) 5.25db) H-2a' 1 .35 -1 .66m 1 .69-1 .48n H-2e '2.24 - 1 .94m 1 .69-1. 4Sm H-3 '4 .47-4, 42m K-4' 5.595sb) 3.2 9 sb 'H-5' 4.47-4.42mb) H - 6 '1 .232dfc' 1. 16db- H-1 ”5.547db3 5 .19 db ^ H-2 a '' 1 .85-1 .66m 1 .69-1 .48m H-2e '' 2 .24 -1 .94m 1.69-1 .48m H-3 ”4. 47 -4. 42m H-4 ”5. 5 8 9 s b ^ 3.26sb · * H-5 ”4 .309qb ^ 3.79qb 'H - 6” 1 · 14 7db ^ 1. 12db ^ OH- 4 1 1.90 2 s OH-6 12.804s OH-11 13.683s.

OH-9 5. 2S7s NHTFA 6.29d / 6.24d pNB: 8.30-8.18m I!

Table 3 - Part 2 39 90777 25C) 26e'h) 273'f ';) H -1 ”. S 5 d "7.50ά 7.Sdd H- 2 7.6 ό t 7. 5 51 7.6-t H - 3 7. 27d 7 .09d 7.2-idd H - 7 5.15m 5.0 t H-Sa 2.29m 1. 83 -1, 39m H-Sb 2 .29r 1.83 -1.39m H- 1 0 4 .9S S 4.92 s H-13a 1.93-1 .68m 1.83 - 1. 3 9 m H-13 b 1. 93-1.6Sm 1 .83- 1 .39m H - U 1. 15 r 1. 03: 1 .04t H-1 '5 .4 5 d 5 .4-db' '5.46051 H- 2 a' 1 .S5ddd 1 .83 -1 .3 9τπ H-2e '2.35ddd 1 .83 -1, 39m H-3' 4 .28m 2.8-2 .5ru H - 4 '4.83t 3.09tbj k ·) H - 5' 4.50dq 5. S 5 dq “'

K M

‘H3-6’ 1 .2 7d 1 .33d “'1 .51d' H-1” 5 .50d 5.35db1 S.42db) H - 2 a '' 1. 76ddd 1 .83 -1 .39m H - 2 e '' 2.0 2 ddd 1 .83 -1, 39n H - 3 '' 4.34m 2.8-2.3m H - 4 '' 4 .7 41 3.01tbj H-5 ” 4. 1 2dq 3. "0dqb 'H.-6' * 1 .23d 1 -33db) 1.27dbl OH-4 12.01s 12. 0 7 s OH-6 12.84s 12.84s OH-11 13.71s 13.60s OH-9 3.30s 3.53s NHTFA 6.39d / 6.33d pNBz 8. 02-8.36m

Table 3 - Part 3 40 28e) 29 H -1 7.94jd 7.9 0 dc H - 2 7f76t; 7, 7 1 t H-3 7.3ödd 7.52dd H-7 5 j 221 5, 1 On H-Sa H-Sb H-10 S, 1 2 s 4; 96 s H- 1 3 a 2, 08-1, 79171 H-15b 2.08-1, 79m H.-14 1.21t 1.09t H-1 '5.53db) 5.38 sb' H-2a '2.08-1? 79m H-2e' 2.08 - 1.79m H-3 '4, 55 -4,52n 2, "Sr, H-4' 4.95Γ 2 r 921 H-5 '4. 55 -4.32m 3.83dq H - 6 '1, 37dUj 1, 34 dw "H-1" 5, 4 5 db ^ 5f37sb} H-2 a' '2.08-1, 79m H-2 e '' 2.08-1.79m H-3 '4.55-4. 3 2 m 3.04m H-4 ”5.71 s 3.37 s H-5” 4.55-4.32m 3.96 q H- -6 '' 1, 28db ^ 1, 28db) OH - 4 12.09 s OH-6 12.93s OH-Π 13.83s OH-9 3.41s NHTFA 6, S4d / 6.25d pNBc 8. 36-8, 2m

II

Table 3 - part 4 41 90777 30e'k) 31e) H - 1 7 7 8: d 7, 8 9 d H-: 7,46t 7 .71t H-5 7,3 1 d 7, 3 2 d H- 7 5, 23s 5.13t H-8a 2.05-2 f 02m 1.9-1, 65m H-8b 2, 0 5 - 2.0 2τπ 1, 9-1, 65m H- 1 0 4 799 s 4.95 s H-13 a 1.95-1 <74m 1 .9-1.65m H-13b 1, 95-1, 74m 1.9-1, 65m H- -14 1, 15l 1 f 091 H -1 '5.54a 5.46p H-2a' 1,193-1.74m H-2e '2.21m H - 3' 2,6 9ddd H-4 '5 j54s 3.67s H-5' 4 r 274 4.02q H- -6 '1, 26d 1, 5701 ^

H-1 ”5.6 8 d S, 37dDJ

H-2a '' 1, 93-1, 74m H-2e ”2,21m H-3 '' 4,44ddd 2,76m H-4 '' 4 7 79t 2,85t H-5” 4,16dq H3- 6 '' 1.21d 1 f50db) OH-4 12.07s OH - 6 12; 88 s OH-11 13.7S s OH-9 NHTFA 6.58d pNBz 8 ^ 27-8} 08m

Claims (10)

A process for the preparation of cytostatically active compounds of formula (I) and their salts with inorganic and organic acids, wherein in formula 2 15 is hydrogen or a radical, of formula (II) ch3 X · 4 and R is hydrogen or a radical of formula II, and in formula II R 1 is hydrogen, hydroxy or benzyloxy, R 7 is NH 2, NH-acyl (C 1 -C 8), N (alkyl) 2 (C 1 -C 8), NH (CH 2 CN) or hydroxy and R 2 is hydrogen or iodine , and the radical of formula II belongs to the series of carbohydrates L-2 4 30, with the exception of compounds in which R = R = H, 4 2 R = H and R = αL-daunosaminyl or αL-rhodosaminyl 2 4 or 4'-acyl-αL- rhodosaminyl, R = R = over αL-rhodosaminyl 2 4 or 4'-acyl-αL-rhodosaminyl or R = H. and R = α-L-rhodosaminyl or αL-daunosaminyl, 35 characterized in that II 90777 43 a) a compound of the formula HO OH OH O HO OH 10 is selectively protected in the 7- and 9-positions by the structure (III) \ X III / 15 wherein X is a common bidentate protecting group in carbohydrate chemistry, preferably alkylboronyl, phenylboronyl, orthoalkylcarboxylic acid alkyl ester, preferably orthomoformic acid methyl ester or ortho-acetic acid ethyl ester, ketal or acetal, preferably isopropylidene or benzylidene, followed by bi) glycosidation at the 10-position by reaction with a functionalized carbohydrate of general formula V or VI 25 CH3 ch3 "it- '.' 'Ö« R S8 R 30 wherein QR is as defined above, R1 is hydrogen, protected hydroxy or benzyloxy, R71 is NH-acyl (C1-C8), N (alkyl) 2 ( C1-C8) or protected hydroxy, and 44 g of R is an oxygen-bonded acyl such as aliphatic acyloxy (C1-C8), benzoyloxy or substituted benzoyloxy, or 5 b2) protecting the 10-hydroxy group acyl -, trimethylsilyl or tetrahydropyranyl, c) deprotection at the 7- and 9-positions, d) glycosidation at the 7-position by reaction with a functionalized carbohydrate of formula V or VI as defined above, e) removal of the acyl- , a trimethylsilyl or tetrahydropyranyl group, f) the 10-position of the compound obtained in step e is glycosylated by reaction with a functionalized carbohydrate of formula V or VI as defined above, and g) if and / or R 1 * is protected hydroxy, deprotect this group, making you want in the case of a compound of formula I having a radical of formula II only in the 7-position, the above-mentioned process steps a, b2, c, d, e and g are carried out; if desired, a compound of formula I having a radical of formula II only in the 10-position is subjected to the above-mentioned process steps a, bx, c and 25 g; and, if desired, a compound of formula I having a radical of formula II in both the 7- and 10-positions is subjected to the above-mentioned process steps a, blf c, d and g or process steps a, b2, c, d, e, f and g; and, if desired, hydrolyzing the NH acyl group R to give a compound of formula I wherein R is ΝΗ-; and 7z alkylating the NH_ group R to give a compound of formula I Δ 7 wherein R is N (alkyl); or 7z the N1 group R is converted by reaction with iodoacetonitrile or bromoacetonitrile in the presence of a suitable base to NH1Cl2N). of 90777 45 For the purpose of determining the cytostatic activity of a compound of formula (I) 5 H 0 HO OR4 io 'H' ^ 2 OH 0 HO OR ^ och salter som with the image of an organic or organic syrup having a formula 2 R Väte eller en radlkal med formuleln (II) 15 ch3 Vv. II 20 R 2 H8 4 or R is a compound or a radical of formula II and a Form II II R, a hydrogen or a benzylox, 25 R7 is NH2, NH-acyl (C1-C8), N (alkyl) 2 (C1-C8), NH (CH2CN) or hydroxy and R® is iodine or radical of formula II to the L-series of the three 2 4 hydrate, with the meanings obtained, in which R = R = H, 4 2 30 R = H and R * αL-daunosaminyl or αL-rhodosaminyl 2 4 or 4'-acyl-αL-rhodosaminyl, R * R = αL-rhodosaminyl 2 4 or 4'-acyl-αL-rhodosaminyl or R = H and R * aL-rhodosaminyl or aL-daunosaminyl, kännetecknat därav, att 46 a) en förening med formuleln O HO OH 5 OH O HO OH skyddas selectively i 7- and 9-colored with structure 10 (III) ^ X III color X is in the case of the hydrolytic group of the skydds-15 group, alkylboronyl, phenylboronyl, alkyl esters of orthoalkylcarboxylic acid, methyl orthomyric acid methyl esters or ethyl esters of orthoethylsulfuric acid, ethyl or acetic acid, ethyl acetate -staining glycosylated compounds in the reaction and functionalization of the dihydrate with all the compounds of formula V or VI CH 25 CH3 _ v ^ VX 715 R R R 30 color Q R betecnar samma som ovan, är väte, shielded hydroxyl or benzyloxy, R 1 and NH-acyl (C1-C8), N (alkyl (C1-C8) or shielded hydroxy and g 35 The genome of a compound of acyl, aliphatic acyloxy (C1-C8), benzoyloxy or substituted benzoyloxy, or II 90777 47 from 7 to 9 and 9-starch, 5 d) 7-starch glycosylated moieties and reactions with a defined functionalized kolhydrate with formulas V or VI, e) an acyl-, trimethylsilyl- or tetrahydropyranyl group having the same 10-starch content , 10 f) 10-addition and the addition of glycosidic compounds in the reaction and the definition of functionalized kolhydrates in formulas V or VI, and g) if R and / or R 'are substituted by hydroxyl, preferably from the group, 15 varvid ovan nämnda förfarandesteg a, b2, c, d, e och g ut-förs dä man self-employed in the formulation with Formula I in the form of radio with Formula II itself i 7-ställning; ovan nämnda förfarandesteg a, blf c och g utförs dä man önskar en förening med formuleln I med en radical med formuleln II itself i 20 10-ställning; och ovan nämnda förfarandesteg a, bt, c, d och g eller förfarandesteg a, b2, c, d, e, f och g utförs dä man önskar en förening med formuleln I med en radical med formuleln II bäde i 7- och i 10 -ställning; and 25 hydrolysers of the NH acyl group R for 7 and 7 of Formula I, color R and NH0; and 7 is an alkyl group in the NH_ group R for a mixture of 7 or more of formula I, color R is N (alkyl) 9; or 7 of the N1 ^ group in the reaction of the reaction with 30 iodoacetonitrile or bromoacetonitrile in the heat of the NHiC (CN group).